These data together with our own findings of higher expression of IL-8, CXCR1, and CXCR2 in HPV-negative HNSCC highlight the potential for CXCR1/2 blockade as a therapeutic strategy in this patient population. Here, CXCR2 is linked to head and neck squamous cell carcinoma.